Cytotoxicity of recombinant DT385.

Cells were treated with varying concentrations of DT385 for 3 days and cell viability was quantified by the CellTiter 96 Aqueous (Promega) assay as described in the legend to Figure 1. In order to determine the effect of double DT385 treatment, cells were treated with varying concentrations of DT385 for 2 days, washed with PBS and the procedure repeated for aCells were treated with varying concentrations of DT385 for 3 days and cell viability was quantified by the CellTiter 96 Aqueous (Promega) assay as described in the legend to Figure 1. In order to determine the effect of double DT385 treatment, cells were treated with varying concentrations of DT385 for 2 days, washed with PBS and the procedure repeated for another 2 days (2 treatments). To allow comparison of single and double treatments, one group of cells were incubated with varying concentrations of DT385 for 4 days (1 treatment).
IC50 is the concentration of DT385 reducing cell viability to 50% after 3 days. Strong: IC50 is less than 0.5 µM; intermediate: IC50 is between 0.5 µM–1.5 µM; weak: IC50 is greater than 1.5 µM.
ND: Not determinable, the inhibition of cell viability by compounds was less than 20% at the concentration of 2.4 µM.
M: measured in this study. Cells were grown in 96-well plates and measured daily by using the CellTiter 96 AQueous (Promega) assay. The doubling time of the cells was calculated from the exponential portion of the growth curve. nother 2 days (2 treatments). To allow comparison of single and double treatments, one group of cells were incubated with varying concentrations of DT385 for 4 days (1 treatment).